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Abstract
Background: Hepatic resection remains the treatment of choice for patients with colorectal liver metas-
tases (CLM). Indications for hepatic resection have been extended to include extrahepatic lymph node
groups, resulting in increased survival benefits. The identification of specific lymph pathways and involved
nodes is necessary to support the development of guidelines for a more focused approach to the
management of this disease. The feasibility of sentinel node mapping should be investigated to define
specific lymphatic groups involved in CLM.
Methods: Scientific papers published from 1950 to 2012 were sought and extracted from the MEDLINE,
PubMed and University of Melbourne databases.
Results: Several studies have reported microscopic lymph node involvement in 10–15% of patients
undergoing hepatic resection for CLM in which no macroscopic involvement was evident. In retrospect,
over 80% of lymphadenectomies are proven unnecessary. Traditional imaging modalities have limited
predictive value in detecting lymph node involvement. Sentinel node mapping has proved an extremely
accurate tool in detecting lymph node involvement and can identify patients in whom lymphadenectomy
may be beneficial.
Conclusions: Current imaging techniques are inadequate to detect microscopic lymph node involve-
ment in patients with resectable CLM. The use of sentinel node mapping is proposed to identify nodal
groups involved and provide management strategies.
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Introduction
The spread of colorectal liver metastases (CLM) has predomi-
nantly focused on tumour angiogenesis and subsequent dissemi-
nation by the systemic circulation.1–3 The role of lymphatics in
the spread of CLM remains controversial.4 Recent studies have
indicated that the excision of lymph node groups in association
with liver resection may result in significant survival benefits.5,6
The issue of which specific node groups should be excised
to offer this survival advantage is subject to controversy.7 At
present, the accurate identification of potentially involved nodal
groups is difficult because the pathways of lymph drainage in the
liver are variable and current imaging techniques are limited.8
Lymphadenectomy is currently performed on an empirical basis
and minimal effort is made to identify the specific involvement
of a particular group.9 The identification of lymphatic pathways
from the liver may result in a more selective or anatomically
correct lymphadenectomy combined with liver resection for
CLM. The concept of sentinel node mapping is an option which
remains to be investigated.
Aims of the study
The aims of this review were to: (i) summarize current knowledge
of lymphatic drainage of the liver and the accuracy of current
imaging techniques used to identify lymph node involvement; (ii)
define current practice with reference to approaches to lym-
phadenectomy with liver resection, and (iii) propose sentinel node
mapping and selective lymphadenectomy in patients with resect-
able CLM.
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Materials and methods
Search strategy
Studies reporting the lymphatic drainage of the liver and out-
comes of patients with CLM undergoing lymphadenectomy and
liver resection were reviewed. Methods to detect lymph node
involvement in these patients were also summarized. A search was
conducted using the following key terms: ‘colorectal metastases’;
‘liver resection’; ‘hepatic lymphatic system’; ‘lymphatic node
involvement in colorectal liver metastasis’; ‘clinical outcomes of
lymphadenectomy’; ‘imaging modalities used to predict lymph
node involvement in colorectal liver metastasis’, and ‘sentinel node
mapping’.
The search was conducted in the MEDLINE, PubMed and Uni-
versity of Melbourne databases for materials published from 1950
until 2012 in English.
Study selection
Potential articles were identified using this search strategy. Titles
and abstracts were screened by the primary reviewer and the study
inclusion criteria applied. Any papers for which inclusion was
contentious were discussed and the issue resolved by the consen-
sus of all of the present authors. Studies that did not meet the
inclusion criteria were excluded.
Inclusion criteria
Studies describing clinical treatment outcomes were required to
report at least one of the following: incidences of microscopic
involvement of lymph nodes; the sensitivity, specificity, accuracy
and predictive values of prognosis using different imaging
modalities, and 5-year survival rates.
Exclusion criteria
Articles published in languages other than English and papers
reporting clinical treatment studies that did not incorporate the
parameters outlined in the inclusion criteria were excluded from
analysis.
Results
A total of 48 studies published from 1950 to 2012 were found to
meet the inclusion criteria and were included for analysis (Fig. 1).
Lymphatic drainage of the liver
The liver produces between a third and half of the total lymph
production of the body.10 Most of the lymph in the liver is formed
in the perisinusoidal space (space of Disse) and is subsequently
drained into the lymphatics of the surrounding intra-lobular
portal triad.10 The lymphatic drainage of the liver to extrahepatic
nodes is complex and unpredictable and features considerable
overlap to multiple sites.10 There are two lymphatic systems in the
liver, identified, respectively, as the superficial and the deep lym-
phatic systems.11 The superficial vessels form a complex capillary
network under the capsule of the liver, in which four broad areas
of drainage are characterized by variability and cross-drainage.10
Detailed lymph pathways are presented in Fig. 2.12
Detection of perihepatic nodal involvement
The incidence of perihepatic lymph node involvement in patients
undergoing resection for CLM varies from 10% to 30%9,13,14 and
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Figure 1 Flow diagram showing the process by which studies were selected for inclusion in this review
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3–20% of patients show microscopic involvement (Table 1).8,15–17
Over 80% of these dissections are proven in retrospect to be
unnecessary and carry potential risk for added morbidity, espe-
cially for bile duct or vascular injury.18 Therefore, detecting micro-
scopic disease is significantly important and clinically relevant
because the excision of such disease allows for improved
survival.19
Several studies have suggested a number of preoperative predic-
tive factors for portal lymph node involvement in patients with
CLM.13,20,21 These factors include: multiple liver metastases (more
than three); tumour involvement of >15% of the liver; synchro-
nous metastases; anterior location of metastases in the liver (espe-
cially in segments IV and V); elevated carcinoembryonic antigen
(CEA) levels (>118 ng/l); the presence of solitary resectable peri-
toneal deposits, and poor tumour differentiation.13 A controversial
issue is the role of lymph node sampling without a complete
dissection of the hepatic hilum and the coeliac trunk.15 Intraopera-
tive assessment based on macroscopic inspection, manual
palpation (the procedures used by most surgeons) and the exami-
nation of frozen lymph node sections suspected of metastatic
involvement are controversial.15 Clinical assessment at operation
identifies approximately 40% of involved nodes.8 Kokudo et al.
used random sampling to determine probable lymph node involve-
ment of right- and left-side liver lesions, and concluded this to be
an effective technique.22 Other authors have not found a relation-
ship between the site of liver metastasis and specific lymphatic
groups. Elias et al. found non-contiguous nodal involvement (skip
lesions).13 Moszkowicz et al. recently showed that the metastatic
status of lymph nodes could not be predicted based on the number,
size or location of CLM. Rau et al. showed in a study of 76 patients
undergoing liver resection for CLM, metastatic lymph nodes were
identified in the hepatic pedicle in 20% of patients.8 In >27% of
these patients, preoperative computed tomography (CT) and
intraoperative evaluation did not indicate any suspicion of this
involvement.8 The use of intraoperative ultrasound may have a role
in identifying suspicious nodes for selective biopsy.23
Imaging modalities
Both CT and magnetic resonance imaging (MRI) have been used
routinely in the preoperative staging of patients with CLM.
(a) (b)
Figure 2 Graphic representations of the (a) superficial and (b) deep lymphatic systems. (Source: ‘Patterns of spread of disease from the liver’,
Fig. 10 and Fig. 9; Meyers et al.12 Reprinted with the kind permission of Springer Science + Business Media BV)
Table 1 Incidences of microscopic lymph node involvement in patients with colorectal liver metastases
Authors (year) Patients undergoing
curative resection, n
Patients with microscopic lymph
node involvement, n (%)
Elias et al. (1996)13 100 14 (14%)
Laurent et al. (2004)16 156 23 (15%)
Jaeck et al. (2002)18 160 17 (11%)
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However, positron emission tomography (PET) scanning appears
to be more accurate than MRI or CT in detecting node involve-
ment. A comparison of the various imaging modalities in current
use is summarized in Table 2. A recent study by Grobmyer et al.
involving 48 patients treated at the Memorial Sloan–Kettering
Cancer Center found a low incidence of occult disease (2.1%) in
patients in whom PET and CT were negative.24 When these inves-
tigations were combined with clinical assessment, all microscopic
involvement was detected (n = 39). In several studies of staging for
gastric carcinoma, pancreatic cancer and hilar cholangiocarci-
noma, endoscopic ultrasound (EUS) has proved a useful tool, with
specificity and sensitivity rates of >90%.25 One study looking at
oesophageal cancer achieved a concordance of 95% for portal
nodes when EUS-guided fine needle aspiration (EUS-FNA) was
correlated with histological diagnosis.23 However, the role of EUS
in detecting lymph node involvement in patients with resectable
CLM has not been established.23
Sentinel node identification
The unpredictability and variability of lymphatic drainage from
the liver, the presence of skip lesions and the limitations of current
imaging techniques have raised doubt regarding the feasibility of
sentinel node mapping in patients undergoing liver resection for
CLM.26
In a small human study, Kane et al. undertook lymph node
mapping in 11 patients (13 procedures) undergoing hepatic
resection for CLM using isosulphan blue staining.27 Using this
technique, lymph nodes were specifically identified in seven of
13 procedures using intrahepatic dye injection in a single hepatic
segment. At the time of resection, a meticulous search for ext-
rahepatic disease was carried out and examination of the porta
hepatis identified suspicious lymph nodes that were biopsied. In
three of the seven procedures, more traditional methods had
failed to identify at-risk nodes prior to staining. All biopsied
nodes were negative for tumour on histological staining, a
finding that may reflect the small number of patients. All liver
segments were injected to determine lymphatic pathways;
however this did not reveal any predictable overall pattern of
segmental lymphatic drainage. On injection, it was noted that
the majority of lesions in segments IV and VI opacified porta
hepatis lymphatics. The falciform ligament was identified as a
route for lymphatic drainage in three patients.27 The technique
demonstrated an increased capacity to identify lymph nodes
compared with traditional methods, but remained subject to
limitations. The accuracy of lymph node mapping is highly vari-
able according to the substance used. In particular, mapping
with blue dye alone has been associated with lower rates of iden-
tification compared with the use of blue dye in combination
with radioactive tracers.28 In addition, the variability of lymph
node identification using lymphatic mapping is associated with
the site of injection, adequacy of surgical training and the pre-
cision of the surgery.29,30 Overall, however, the technique
appeared to be safe and feasible.27
To the present authors’ knowledge, no studies have been under-
taken to examine the outcomes of modern node mapping tech-
niques using a combination of dyes and radioactive tracers and
more sophisticated immunohistological techniques to identify
tumour involvement of sentinel nodes. Such techniques may
increase the accuracy of nodal group involvement, avoid unnec-
essary dissection and minimize complications. Several studies
involving other malignancies have confirmed that the status of
sentinel nodes is an important predictor of recurrence and may
identify subgroups of patients for the excision of lymph node
groups that are likely to be involved.31–33
Table 2 Comparison of the limitations of current imaging modalities
Authors
(year)
Patients,
n
Nodes
sampled
per patient,
mean  SD
Procedure Sensitivity Specificity Negative
predictive
value
Positive
predictive
value
Rau et al.
(2012)8
76 3.2  2.1 Results of preoperative CT
were compared with
pathologic findings
N/A N/A CT: 85% CT: 56%
Grobmyer
et al.
(2006)24
100 3.2  0.2 Preoperative CT scans and
PET scans were reviewed
by radiologists. Clinical
assessment, CT and PET
scan results were
compared with pathologic
status of lymph nodes
CT: 92% CT: 40% CT: 95% CT: 30%
PET: 57% PET: 100% PET: 88% PET: 100%
Clinical
assessment:
90%
Clinical
assessment:
87%
Clinical
assessment:
99%
Clinical
assessment:
30%
Naini et al.
(2008)23
61 N/A EUS-FNA procedures of the
lymph nodes were
analysed by correlating
the FNA results with
histological or clinical
diagnosis
EUS-FNA:
84%
EUS-FNA:
92%
EUS-FNA:
89%
EUS-FNA:
88%
SD, standard deviation; N/A, not available; CT, computed tomography; PET, positron emission tomography; EUS, endoscopic ultrasound; FNA, fine
needle aspiration.
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Current status of lymphadenectomy with liver
resection in CLM
Until recently, extrahepatic lymph node involvement was consid-
ered a contraindication to liver resection for CLM.34 This view was
based on poor survival figures derived from small series of
patients in an era of ineffective chemotherapy, inadequate staging
modalities and poor understanding of tumour biology.34–36 More
recently, several studies36–40 have investigated the relationship
between 5-year survival and the presence or absence of lymph
node involvement (Table 3).
Several factors influencing survival have been identified in this
context. These include the number and sites of involvement,
tumour load and patient age. Poor prognostic factors are
adversely affected by the number of sites of extrahepatic disease.
Extrahepatic disease that occurs at more than one site has an
adverse effect on prognosis: survival in extrahepatic disease at
more than one site is 0%, whereas survival in extrahepatic
disease at one site only can reach 30%.41–43 Macroscopic disease
is associated with poorer survival compared with microscopic
disease.16 Microscopic disease detected by immunohistochemical
methods appears to afford a better prognosis than that detected
by routine haematoxylin and eosin staining.15 The presence of
more than eight liver metastases also adversely affects the out-
come.44 Both Cady et al.45 and Ekberg et al.46 reported the total
number of metastases as a significant prognostic factor. Other
reports indicate that, provided a complete negative margin (R0)
resection is achieved, the site rather than the number of metas-
tases is the predominant prognostic influence.47,48 Patient age of
>60 years also appears to be an independent indicator of a poor
prognosis.49 It is important that patients who undergo nodal dis-
section do not suffer significant morbidity in relation to the con-
comitant liver resection and that R0 resection can be achieved.
Most studies show that the morbidity added by combining lym-
phadenectomy with liver resection is minimal.6,7 Risks include
haemorrhage, lymphocoele, vascular injury or bile duct ischae-
mia and subsequent stricture formation.5 All patients undergo-
ing liver resection should receive appropriate neoadjuvant
chemotherapy to achieve responsive or stable disease with no
evidence of progression.
In general, the site of nodal involvement appears to be an
important prognostic factor. Jaeck described two distinct areas of
hepatic pedicle lymph node involvement: area 1 involves the hepa-
toduodenal ligament and retropancreatic area, and area 2 involves
the common hepatic artery and coeliac axis.9 Jaeck reported
lymph node metastases occurred in between 10% to 20% of
patients. Furthermore, when lymph node metastases are found
within area 1, an extended lymphadenectomy should be per-
formed. However, resection of CLM for involvement in area 2
demonstrated no survival benefit.9 Several studies, including that
of Jaeck et al.,18 have reported correlations between the distinct
areas of lymph involvement and 5-year survival36,40,51 (Table 4).
However, this difference in survival according to which of the two
areas is involved has been challenged by Oussoultzoglou et al.,
who reported no difference in survival across a cohort of similar
patients with involvement in areas 1 or 2 and concluded that there
is no need to identify specific areas of local involvement in the
hepatic pedicle.50
Conclusions
The imaging modalities currently used in the routine staging of
CLM patients are inadequate to detect microscopic lymph node
involvement. Recent studies have highlighted the potential signifi-
cance of lymph node involvement in the survival of CLM patients
following resection. Several studies have reported survival advan-
tages in patients who undergo nodal dissection with liver resec-
Table 3 Summary of data for patients undergoing curative resection of colorectal liver metastases
Authors (year) Patients, n Patients with
positive nodes, n
5-year survival in
node-negative patients, %
5-year survival in
node-positive patients, %
Rodgers & McCall (2000)37 2803 145 Not specified 3%
Beckurts et al. (1997)38 126 35 22% 0%
Nakamura et al. (1992)39 31 6 Not specified 45%
Adam et al. (2011)40 186 56 55% 28%
Pulitano et al. (2012)36 1629 61 Not specified 18%
Table 4 Rates of 5-year survival according to areas of lymph node involvement
Authors (year) 5-year survival (area 1) 5-year survival (area 2)
Jaeck et al. (2002)18 38% 0%
Adam et al. (2011)40 25% 0%
Johnston et al. (2012)51 30% 0%
Pulitano et al. (2012)36 30% 14%
Oussoultzoglou et al. (2009)50 27.5% 26.7%
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tion in the absence of macroscopic lymph node involvement.
However, in retrospect, many of these routine nodal dissections
without macroscopic lymph node involvement appear to be
unnecessary. In order to rationalize and deliver targeted manage-
ment plans for patients with CLM, the accurate identification of
patients with microscopic lymph node involvement who are likely
to benefit from nodal dissection is clinically significant. The appli-
cation of sentinel node mapping as a novel imaging modality to
identify microscopic lymph node involvement in CLM warrants
further active research.
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